Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/38075
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nasreddine, Rakan | - |
dc.contributor.author | Yombi, Jean Cyr | - |
dc.contributor.author | Darcis, Gilles | - |
dc.contributor.author | Florence, Eric | - |
dc.contributor.author | Allard, Sabine D. | - |
dc.contributor.author | De Scheerder, Marie-Angelique | - |
dc.contributor.author | Henrard, Sophie | - |
dc.contributor.author | Demeester , Remy | - |
dc.contributor.author | MESSIAEN, Peter | - |
dc.contributor.author | Ausselet, Nathalie | - |
dc.contributor.author | Loeckx, Matthias | - |
dc.contributor.author | Delforge, Marc | - |
dc.contributor.author | De Wit, Stephane | - |
dc.date.accessioned | 2022-09-14T07:23:47Z | - |
dc.date.available | 2022-09-14T07:23:47Z | - |
dc.date.issued | 2023 | - |
dc.date.submitted | 2022-08-25T09:10:20Z | - |
dc.identifier.citation | HIV medicine (Print), 24 (3), p. 267-278 | - |
dc.identifier.uri | http://hdl.handle.net/1942/38075 | - |
dc.description.abstract | Objectives A paradigm shift from three-drug regimens to two-drug regimens (2DRs) is currently taking place in real-world clinical practice. This study aimed to describe the efficacy, durability, and tolerability of dolutegravir (DTG)/lamivudine (3TC) and DTG/rilpivirine (RPV) in a real-world setting. Methods This was a retrospective, observational, multicentre (ten centres in Belgium) study involving adult treatment-naive and treatment-experienced people living with HIV on DTG/3TC or DTG/RPV between 1 January 2019 and 30 September 2020. The primary endpoint was rate of virological suppression (VS; plasma HIV-1 viral load [VL] <50 copies/ml) using an on-treatment analysis. Main secondary endpoints included the proportion of patients that experienced loss of VS (LVS; defined as two consecutive HIV-1 VLs of >200 copies/ml after initially achieving VS) and a resistance analysis at the time of LVS; rate, incidence, and reasons for discontinuation of treatment (stopping treatment or changing any component of the 2DR); and change in weight, along with the proportion of patients reporting a >10% weight gain. Ordinal logistic regression analysis examined associations between baseline variables and >10% on-treatment weight gain. Results Overall, 948 patients were included, of whom 734 (77%) were on DTG/3TC and 214 (23%) were on DTG/RPV. Baseline characteristics included 54% aged >= 50 years, 31% female, 31% Black sub-Saharan African, 95% treatment-experienced, and 8% with HIV-1 VL >= 50 copies/ml. Through 48 weeks, the rate of VS for the overall cohort was 98.3% (99.1% with 3TC; 96.2% with RPV). LVS was observed in 0.5% (n = 5) of the overall population (n = 1 [3TC group], n = 4 [RPV group]). There were 40 treatment discontinuations (4.2%, n = 27 [3TC group]; n = 13 [RPV group]), corresponding to an incidence of 4.7 per 100 patient-years. The most common reason for discontinuation was an adverse event (1.4%), with neurotoxicity the most frequent (0.5%). Median on-treatment weight gain at week 48 was 1 kg (interquartile range [IQR] -1-3) overall, 1 kg (IQR -1-3) in the 3TC group, and 2 kg (IQR 0-4) in the RPV group. A >10% weight increase was observed in 6.3% of patients. Regression analysis showed that being on a tenofovir disoproxil fumarate-based regimen prior to 2DR initiation was the only variable associated with a >10% increase in weight from baseline (odds ratio 3.48; 95% confidence interval 1.13-10.68; p = 0.038). Conclusion In this real-world analysis, the 2DRs analysed were effective, durable, and safe for both treatment-naive and treatment-experienced patients. A slight increase in weight was associated with these regimens. | - |
dc.description.sponsorship | This study was supported by ViiV Healthcare. | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.rights | 2022 British HIV Association. | - |
dc.subject.other | dolutegravir | - |
dc.subject.other | lamivudine | - |
dc.subject.other | rilpivirine | - |
dc.subject.other | HIV | - |
dc.subject.other | real-world data | - |
dc.subject.other | virological suppression | - |
dc.title | Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium | - |
dc.type | Journal Contribution | - |
dc.identifier.epage | 278 | - |
dc.identifier.issue | 3 | - |
dc.identifier.spage | 267 | - |
dc.identifier.volume | 24 | - |
local.bibliographicCitation.jcat | A1 | - |
dc.description.notes | Nasreddine, R (corresponding author), St Pierre Univ Hosp, Div Infect Dis, Rue Haute 322, B-1000 Brussels, Belgium. | - |
dc.description.notes | rakan.nasreddine@stpierre-bru.be | - |
local.publisher.place | 111 RIVER ST, HOBOKEN 07030-5774, NJ USA | - |
local.type.refereed | Refereed | - |
local.type.specified | Article | - |
dc.identifier.doi | 10.1111/hiv.13373 | - |
dc.identifier.pmid | 35938381 | - |
dc.identifier.isi | 000837057800001 | - |
dc.contributor.orcid | Darcis, Gilles/0000-0001-8192-1351; Nasreddine, | - |
dc.contributor.orcid | Rakan/0000-0002-1265-1500 | - |
local.provider.type | wosris | - |
local.description.affiliation | [Nasreddine, Rakan; Delforge, Marc; De Wit, Stephane] St Pierre Univ Hosp, Brussels, Belgium. | - |
local.description.affiliation | [Yombi, Jean Cyr] Clin Univ St Luc, Brussels, Belgium. | - |
local.description.affiliation | [Darcis, Gilles] Liege Univ Hosp, Liege, Belgium. | - |
local.description.affiliation | [Florence, Eric] Inst Trop Med, Antwerp, Belgium. | - |
local.description.affiliation | [Allard, Sabine D.] Univ Ziekenhuis Brussel, Brussels, Belgium. | - |
local.description.affiliation | [De Scheerder, Marie-Angelique] Ghent Univ Hosp, Ghent, Belgium. | - |
local.description.affiliation | [Henrard, Sophie] Univ Clin Brussels, Erasme Hosp, Brussels, Belgium. | - |
local.description.affiliation | [Demeester, Remy] Univ Hosp Charleroi, Lodelinsart, Belgium. | - |
local.description.affiliation | [Messiaen, Peter] Jessa Hosp, Hasselt, Belgium. | - |
local.description.affiliation | [Ausselet, Nathalie] UCL Univ Hosp Namur Godinne, Yvoir, Belgium. | - |
local.description.affiliation | [Loeckx, Matthias] ViiV Healthcare, Amersfoort, Belgium. | - |
local.uhasselt.international | no | - |
item.fullcitation | Nasreddine, Rakan; Yombi, Jean Cyr; Darcis, Gilles; Florence, Eric; Allard, Sabine D.; De Scheerder, Marie-Angelique; Henrard, Sophie; Demeester , Remy; MESSIAEN, Peter; Ausselet, Nathalie; Loeckx, Matthias; Delforge, Marc & De Wit, Stephane (2023) Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium. In: HIV medicine (Print), 24 (3), p. 267-278. | - |
item.contributor | Nasreddine, Rakan | - |
item.contributor | Yombi, Jean Cyr | - |
item.contributor | Darcis, Gilles | - |
item.contributor | Florence, Eric | - |
item.contributor | Allard, Sabine D. | - |
item.contributor | De Scheerder, Marie-Angelique | - |
item.contributor | Henrard, Sophie | - |
item.contributor | Demeester , Remy | - |
item.contributor | MESSIAEN, Peter | - |
item.contributor | Ausselet, Nathalie | - |
item.contributor | Loeckx, Matthias | - |
item.contributor | Delforge, Marc | - |
item.contributor | De Wit, Stephane | - |
item.fulltext | With Fulltext | - |
item.accessRights | Restricted Access | - |
crisitem.journal.issn | 1464-2662 | - |
crisitem.journal.eissn | 1468-1293 | - |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Efficacy, durability, and tolerability of dolutegravir_lamivudine and dolutegravir_rilpivirine for the treatment of HIV in a real‐world setting in Belgium.pdf Restricted Access | Published version | 230.48 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.